STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED VERTEX PHARMACEUTICALS (EUROPE) LIMITED AND CRISPR THERAPEUTICS AG CRISPR THERAPEUTICS LIMITED CRISPR THERAPEUTICS, INC. TRACR HEMATOLOGY LTD.Collaboration, Option and License Agreement • October 7th, 2016 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • Massachusetts
This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of October 26, 2015 (the “Effective Date”) by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (“Vertex Parent”), and VERTEX PHARMACEUTICALS (EUROPE) LIMITED, a private limited liability company organized under the laws of England and Wales (“Vertex UK” and, together with Vertex Parent, “Vertex”) and, on the other hand, CRISPR THERAPEUTICS AG, a corporation organized under the laws of Switzerland (“CRISPR AG”), CRISPR THERAPEUTICS, INC., a corporation organized under the laws of the state of Delaware (“CRISPR Inc.”), CRISPR THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales (“CRISPR UK”) and TRACR HEMATOLOGY LTD, a UK limited company (“Tracr” and together with CRISPR AG, CRISPR Inc. and CRISPR UK “CRISPR”). Vertex and CRISPR each may be referred to herein
COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • April 5th, 2017 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of August 8, 2016 (“Effective Date”), by and between ADVERUM BIOTECHNOLOGIES, INC., a Delaware corporation having an address at 1035 O’Brien Drive, Menlo Park, CA 94025 (“Adverum”), and EDITAS MEDICINE, INC., a Delaware corporation having an address at 300 Third Street, Cambridge, MA 02142 (“Editas”). Adverum and Editas may be referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION,...Collaboration, Option and License Agreement • May 8th, 2024 • Merus N.V. • Pharmaceutical preparations • New York
This Collaboration, Option and License Agreement (the “Agreement”), effective as of March 5, 2024 (the “Effective Date”), is made by and between:
STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • February 16th, 2016 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Massachusetts
This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of October 26, 2015 (the “Effective Date”) by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (“Vertex Parent”), and VERTEX PHARMACEUTICALS (EUROPE) LIMITED, a private limited liability company organized under the laws of England and Wales (“Vertex UK” and, together with Vertex Parent, “Vertex”) and, on the other hand, CRISPR THERAPEUTICS AG, a corporation organized under the laws of Switzerland (“CRISPR AG”), CRISPR THERAPEUTICS, INC., a corporation organized under the laws of the state of Delaware (“CRISPR Inc.”), CRISPR THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales (“CRISPR UK”) and TRACR HEMATOLOGY LTD, a UK limited company (“Tracr” and together with CRISPR AG, CRISPR Inc. and CRISPR UK “CRISPR”). Vertex and CRISPR each may be referred to herein
FIRST AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • October 6th, 2022 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • California
This First Amendment to Collaboration, Option and License Agreement (this “First Amendment”), dated August 13, 2019 (the “First Amendment Effective Date”), is by and between Nurix Therapeutics, Inc., a Delaware corporation (“Nurix”) and Gilead Sciences, Inc., a Delaware corporation (“Gilead”).
COLLABORATION, OPTION AND LICENSE AGREEMENT BY AND BETWEEN JANSSEN PHARMACEUTICALS, INC., MEIRAGTX UK II LIMITED AND MEIRAGTX HOLDINGS PLCCollaboration, Option and License Agreement • March 26th, 2019 • MeiraGTx Holdings PLC • Biological products, (no disgnostic substances) • New York
This Collaboration, Option and License Agreement (this “Agreement”) is made as of January 30, 2019 (the “Execution Date”), by and between Janssen Pharmaceuticals, Inc., a Pennsylvania corporation located at 1125 Trenton-Harbourton Road, Titusville, NJ 08560, United States of America (“Janssen”), on the one hand, and MeiraGTx UK II Limited, a company organized and existing under the laws of England, located at 25 Provost Street, London N1 7NH, United Kingdom and MeiraGTx Holdings plc, a Cayman Islands corporation located at 430 East 29th Street, 10th Floor, New York, NY 10016, United States of America (MeiraGTx UK II Limited and MeiraGTx Holdings plc, individually or collectively, “MeiraGTx”), on the other hand. Janssen and MeiraGTx are each referred to individually as a “Party” and together as the “Parties.”
AND LICENSE AGREEMENTCollaboration, Option and License Agreement • November 19th, 2021 • Exicure, Inc. • Pharmaceutical preparations • New York
[***] - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.
COLLABORATION, OPTION AND LICENSE AGREEMENT between EXICURE, INC. and ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED November 13, 2019Collaboration, Option and License Agreement • March 10th, 2020 • Exicure, Inc. • Pharmaceutical preparations • New York
This COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of November 13, 2019 (the “Effective Date”), by and between EXICURE, INC., a Delaware corporation with a place of business at 8045 Lamon Avenue, Suite 410, Skokie, IL 60077 (“Exicure”), and ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED, a private company limited by shares, with a place of business at Clonshaugh Business & Technology Park, Dublin 17, D17 E400, Ireland (“Allergan”). In this Agreement, Allergan and Exicure are collectively referred to as the “Parties” and each individually as a “Party”.
SECOND AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • October 6th, 2022 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • California
This Second Amendment to Collaboration, Option and License Agreement (this “Second Amendment”), dated September 9, 2022 (the “Second Amendment Effective Date”), is by and between Nurix Therapeutics, Inc., a Delaware corporation (“Nurix”) and Gilead Sciences, Inc., a Delaware corporation (“Gilead”).
ContractCollaboration, Option and License Agreement • July 2nd, 2020 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • California
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION, OPTION...Collaboration, Option and License Agreement • November 7th, 2022 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • New York
ContractCollaboration, Option and License Agreement • May 5th, 2020 • New York
EX-10.24 6 a8-kaexhibit1024x11717.htm EXHIBIT 10.24 Exhibit 10.24 EXECUTION VERSION RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT by and between EXICURE, INC. and PURDUE PHARMA L.P. THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. TABLE OF CONTENTS
COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • August 27th, 2021 • iBio, Inc. • Pharmaceutical preparations • Delaware
This Collaboration, Option and License Agreement (together with all Exhibits and Schedules attached hereto, this “Agreement”) is made as of August 23, 2021 (the “Effective Date”), by and between RubrYc Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, located at 733 Industrial Road, San Carlos, CA 94070 (“RubrYc”), and iBio, Inc., a corporation organized under the laws of the State of Texas, located at 8800 HSC Pkwy, Bryan, TX 77807 (“iBio”). RubrYc and iBio are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • March 6th, 2018 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amendment (“Amendment”) is entered into as of January 25, 2018 (the “Amendment Effective Date”), by and between Adverum Biotechnologies, Inc., a Delaware corporation having an address at 1035 O’Brien Drive, Menlo Park, CA 94025 (“Adverum”), and Editas Medicine, Inc., a Delaware corporation having an address at 11 Hurley St., Cambridge, MA 02141 (“Editas”) and amends that certain Collaboration, Option and License Agreement, dated August 8, 2016, by and between Adverum and Editas (the “Agreement”). Adverum and Editas may be referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATION, OPTION AND LICENSE AGREEMENT BetweenCollaboration, Option and License Agreement • August 12th, 2020 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • New York
This Collaboration, Option and License Agreement (the “Agreement”) is made and entered into as of June 15, 2020 (“Execution Date”) and is effective as of the Effective Date (as defined below), between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (“GSK”), and IDEAYA Biosciences, Inc., a Delaware corporation having an office at 7000 Shoreline Court, Suite 350, South San Francisco, CA 94080 (“IDEAYA”). GSK and IDEAYA are sometimes referred to individually as a “Party” and collectively as the “Parties.”
